Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

Research design: It is planned to collect pulmonary nodules confirmed by preoperative CT during the period from January 2021 to June 2020 The peripheral blood and clinical information of 100 patients who underwent surgical operations were classified according to the pathological diagnosis of the patients It is the malignant pulmonary nodule group and the benign pulmonary nodule group. Through single-cell sequencing, flow cytometry analysis and radiomics The purpose of identifying the benign and malignant nature of pulmonary nodules is: ① To predict the benign and malignant nature of pulmonary nodules before surgery; ② Explore evil the differences in the immune microenvironment between patients with sexual and benign pulmonary nodules, and the search for specific markers with clinical value Object ③ Compare the diagnostic sensitivity of the new prediction method with that of traditional tumor markers and explore its role as a predictor The potential for measuring the benign and malignant nature of pulmonary nodules

Inclusion criteria

• Patient underwent a ct examination
• Patient was confirmed to have pulmonary nodules
• Patient has been determined to undergo surgical treatment
• There are clear pathological results
• The clinicopathological data are complete

Exclusion criteria

• Patient has no ct examination results
• Refuse surgical treatment
• Patient has no clear pathological diagnosis
• Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
• Patients with tumor emergencies that require immediate treatment.
• Poor vascular conditions.
• Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
• Patients with hematogenic infectious diseases, such as HBV.
• Patients with psychiatric disorders or severe mental illnesses.
• Patients who have difficulty communicating or are unable to be followed up for a long time